clinical trial · NCT07481604
Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above
CHA Vaccine Institute Co., Ltd.·phase2·not yet recruiting·n = 135
Herpes ZosterShingrixCVI-VZV-001
brief summary
To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.
started
Apr 1, 2026
primary completion
Jan 1, 2027
completion
Jan 1, 2027
last updated
Mar 19, 2026
official title
A Multicenter, Active-controlled, Randomized, Double Blinded, Parallel, Phase II Study to Assess the Immunogenicity and Safety of CVI-VZV-001 in Healthy Adults Aged 50 Years and Above
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol